KDM4B and autoimmune disease: This difference suggests that targeting KDM4B’s epigenetic regulation offers better specificity and therapeutic efficacy compared to methionine restriction, which broadly affects methylation metabolism, indicating KDM4B as an ideal therapeutic target for autoimmune diseases.